Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trialResearch in context

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trialResearch in context

Summary: Background: This phase 2 trial aimed to compare adjuvant icotinib with observation in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage IB non-small cell lung cancer (NSCLC). Methods: We performed a randomised, open-label, phase 2 trial from May 1, 2015...

Full description

Bibliographic Details
Main Authors: Wei Ou, Ning Li, Bao-Xiao Wang, Teng-Fei Zhu, Zhi-Lin Shen, Tao Wang, Wu-Guang Chang, Zeng-Hao Chang, Xin-Xin Hu, Yue Pu, Lie-Ming Ding, Si-Yu Wang
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:EClinicalMedicine
Subjects:
Icotinib
Adjuvant therapy
Stage IB NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023000160

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023000160

Similar Items